摘要
目的观察双虎清肝颗粒治疗慢性乙型肝炎肝纤维化的临床疗效。方法将120例慢性乙型肝炎患者随机分为治疗组(60例)和对照组(60例),治疗组联用双虎清肝颗粒(12g/次,每天2次)和拉米夫定(100mg,每天1次),对照组单用拉米夫定(100mg,每天1次),疗程均为6个月。应用RIA法分别检测治疗前和治疗6个月后各组患者血清LN、HA、PCⅢ、CIV的含量。结果治疗后2组血清LN、HA、PCⅢ、CIV含量均明显下降(P<0.05或0.01),且治疗组明显优于对照组(P<0.05)。结论双虎清肝颗粒对慢性乙型肝炎患者肝纤维化具有明显的干预作用。
Objective To observe the clinical therapeutic efect of Shuanghuqinggan granule in the treatment of liver fibrosis in patients with chronic hepatitis B. Methods 120 patients were randomly divided into the study group and control group ,60 cases per group. The patients in the study group were treated with Shuanghuqinggan granule （12g, Bid） and Lamivudine（ 100 mg, Qd） ,while patients in control group were treated with Lamivudine （100mg, Qd）. Laboratory indicators such as LN ,HA,PCⅢ ,CIV were respectively detected before and 6 months after the treatment. Results After the treatment laboratory indicators such as LN ,HA ,PCⅢ ,CIV were significantly decreasing in both group（ P 〈 0.05 or 〈 0.01 ） , but more notable in study group different from those in control group （ P 〈 0.05 ） . Conclusion Shuanghuqinggan granule is suitable for treating the liver fibrosis of chronic hepatitis B.
出处
《临床合理用药杂志》
2009年第6期7-8,共2页
Chinese Journal of Clinical Rational Drug Use
